维得利珠单抗与抗肿瘤坏死因子在炎症性肠病中严重感染风险的比较:基于瑞典全国登记数据的结果
这项瑞典全国队列研究采用倾向评分匹配的Cox回归,比较维得利珠单抗与抗TNF治疗的炎症性肠病患者严重感染风险。克罗恩病中维得利珠单抗严重感染风险高于抗TNF(HR=1.72),溃疡性结肠炎中两者未见显著差异。两种药物严重感染类型分布似乎不同。
要点
- 克罗恩病中维得利珠单抗严重感染率5.18/100人年 vs 抗TNF 3.54/100人年,HR=1.72。
- 溃疡性结肠炎中维得利珠单抗与抗TNF严重感染风险无显著差异(初始HR=0.80)。
- 两种药物严重感染类型分布似乎不同:抗TNF中肺炎占40%,维得利珠单抗中无肺炎病例。
核心结论
- 克罗恩病患者中维得利珠单抗与抗TNF相比严重感染风险增加,但溃疡性结肠炎中未见此风险增加。
- 尽管如此,两种药物严重感染的整体分布似乎不同。
- 研究结果强调临床需关注感染及两种疗法的安全性特征。
研究设计与样本
- 瑞典全国队列研究,治疗 episodes 来自全国健康登记数据。
- 采用倾向评分匹配队列的Cox回归估计严重感染的风险比(HR),严重感染定义为需住院的感染。
- 克罗恩病共1376个治疗 episodes,溃疡性结肠炎共1294个治疗 episodes。
主要发现
- 克罗恩病中维得利珠单抗严重感染率为5.18/100人年(95%CI=3.98-6.63),抗TNF为3.54/100人年(95%CI=2.50-4.85),HR=1.72(95%CI=1.12-2.65),部分由更多胃肠道感染解释。
- 克罗恩病中与匹配的一般人群队列的0.75/100人年(95%CI=0.59-0.92)相比,维得利珠单抗风险更高(HR=7.00;95%CI=5.04-9.72)。
- 溃疡性结肠炎中维得利珠单抗严重感染率为3.74/100人年(95%CI=2.66-5.11),抗TNF为3.42/100人年(95%CI=2.31-4.89);初始1.1年内HR=0.80(95%CI=0.47-1.36),1.1年后HR=2.03(95%CI=0.65-6.32)(因非比例风险而截断)。
- 抗TNF治疗中肺炎占所有感染的40%,而维得利珠单抗治疗 episodes 中未观察到肺炎病例。
- 溃疡性结肠炎中与匹配的一般人群队列的0.69/100人年(95%CI=0.53-0.87)相比,维得利珠单抗的HR为5.45(95%CI=3.67-8.11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to assess the risk of serious infection in patients with inflammatory bowel disease (IBD) treated with vedolizumab compared with those treated with anti-tumor necrosis factors (TNF) and the general population. METHODS: In this Swedish cohort study, treatment episodes were identified from nationwide health registers. We used Cox regression with propensity score-matched cohorts to estimate hazard ratios (HRs) for incident serious infections, defined as infections requiring hospital admission. RESULTS: During 1,376 treatment episodes in Crohn's disease, the rate of serious infections per 100 person-years (PY) was 5.18 (95% CI = 3.98-6.63) with vedolizumab vs 3.54 (95% CI = 2.50-4.85) with anti-TNF; HR = 1.72 (95% CI = 1.12-2.65), partly explained by more gastrointestinal infections. Compared with the rate of 0.75/100 PY (95% CI = 0.59-0.92) in a matched general population cohort, vedolizumab demonstrated higher risk (HR = 7.00; 95% CI = 5.04-9.72). During 1,294 treatment episodes in ulcerative colitis, the corresponding rates were 3.74/100 PY (95% CI = 2.66-5.11) with vedolizumab vs 3.42/100 PY (95% CI = 2.31-4.89) with anti-TNF; HR = 0.80 (95% CI = 0.47-1.36) during the initial 1.1 years and HR = 2.03 (95% CI = 0.65-6.32) after 1.1 years (truncated due to nonproportional hazards). Pneumonia accounted for 40% of all infections among anti-TNF, whereas no case was observed among vedolizumab episodes. Compared with the rate of 0.69/100 PYs (95% CI = 0.53-0.87) in a matched general population cohort, vedolizumab showed an HR of 5.45 (95% CI = 3.67-8.11). DISCUSSION: Vedolizumab was associated with increased risks of serious infections compared with anti-TNF in Crohn's disease but not in ulcerative colitis. Nonetheless, the panorama of serious infections seemed to differ between the drugs. Our findings underscore the importance of clinical awareness of infections and the safety profile of the 2 therapies.
引用
- Karlqvist S, Sachs MC, Eriksson C, et al. Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers. Am J Gastroenterol. 2024. PMID: 38994835. doi:10.14309/ajg.0000000000002961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。